Skip to content
Open access · CC-BY via OpenAlex

Galactose‐modified duocarmycin prodrugs as senolytics

Ana T.G. Guerrero, Romain Guiho, Nicolás Herranz, Anthony G. Uren, Dominic J. Withers, Juan Pedro Martínez-Barberá, Lutz Friedjan Tietze, Jesús Gil

Aging Cell · 2020 · ▲ 174 citations

Abstract

Senescence(definition) is a stable growth arrest that impairs the replication of damaged, old or preneoplastic cells, therefore contributing to tissue homeostasis. Senescent cells accumulate during ageing and are associated with cancer, fibrosis and many age-related pathologies. Recent evidence suggests that the selective elimination of senescent cells can be effective on the treatment of many of these senescence-associated diseases. A universal characteristic of senescent cells is that they display elevated activity of the lysosomal β-galactosidase, and this has been exploited as a marker for senescence (senescence-associated β-galactosidase activity). Consequently, we hypothesized that galactose-modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. Here, we show that different galactose-modified duocarmycin (GMD) derivatives preferentially kill senescent cells. GMD prodrugs induce selective apoptosis of senescent cells in a lysosomal β-galactosidase (GLB1)-dependent manner. GMD prodrugs can eliminate a broad range of senescent cells in culture, and treatment with a GMD prodrug enhances the elimination of bystander senescent cells that accumulate upon whole-body irradiation treatment of mice. Moreover, taking advantage of a mouse model of adamantinomatous craniopharyngioma (ACP), we show that treatment with a GMD prodrug selectively reduced the number of β-catenin-positive preneoplastic senescent cells. In summary, the above results make a case for testing the potential of galactose-modified duocarmycin prodrugs to treat senescence-related pathologies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1111/acel.13133
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Guerrero, A.T., Guiho, R., Herranz, N., Uren, A.G., Withers, D.J., Martínez-Barberá, J.P., Tietze, L.F., &amp; Gil, J. (2020). Galactose‐modified duocarmycin prodrugs as senolytics. <em>Aging Cell</em>. https://doi.org/10.1111/acel.13133
Vancouver
Guerrero AT, Guiho R, Herranz N, Uren AG, Withers DJ, Martínez-Barberá JP, et al. Galactose‐modified duocarmycin prodrugs as senolytics. Aging Cell. 2020. doi:10.1111/acel.13133.
BibTeX
@article{ana2020Galact, title = {Galactose‐modified duocarmycin prodrugs as senolytics}, author = {Ana T.G. Guerrero and Romain Guiho and Nicolás Herranz and Anthony G. Uren and Dominic J. Withers and Juan Pedro Martínez-Barberá and Lutz Friedjan Tietze and Jesús Gil}, journal = {Aging Cell}, year = {2020}, doi = {10.1111/acel.13133}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings